Cellectar Biosciences Cash Flow from Operating Activities 2010-2024 | CLRB
Cellectar Biosciences cash flow from operating activities from 2010 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
| Cellectar Biosciences Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2024 | $-48 |
| 2023 | $-32 |
| 2022 | $-25 |
| 2021 | $-23 |
| 2020 | $-14 |
| 2019 | $-12 |
| 2018 | $-11 |
| 2017 | $-11 |
| 2016 | $-8 |
| 2015 | $-8 |
| 2014 | $-9 |
| 2013 | $-9 |
| 2012 | $-7 |
| 2011 | $-6 |
| 2010 | $-3 |
| 2009 | $-11 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.012B | $0.000B |
| Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin. | |||